 Receptors, Thrombopoietin
"Receptors, Thrombopoietin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Cell surface receptors that are specific for THROMBOPOIETIN. They contain two central FIBRONECTIN TYPE III DOMAINS and signal through interaction with JANUS KINASES such as JANUS KINASE 2.
| Descriptor ID |
D053628
|
| MeSH Number(s) |
D12.776.543.750.705.852.610
|
| Concept/Terms |
Receptors, Thrombopoietin- Receptors, Thrombopoietin
- Thrombopoietin Receptors
- CD110 Antigens
- MPL Ligand Receptor
- Thrombopoietin Receptor
- Antigens, CD110
|
Below are MeSH descriptors whose meaning is more general than "Receptors, Thrombopoietin".
Below are MeSH descriptors whose meaning is more specific than "Receptors, Thrombopoietin".
This graph shows the total number of publications written about "Receptors, Thrombopoietin" by people in this website by year, and whether "Receptors, Thrombopoietin" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2014 | 1 | 0 | 1 | | 2015 | 0 | 1 | 1 | | 2016 | 0 | 2 | 2 | | 2021 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Receptors, Thrombopoietin" by people in Profiles.
-
Zoine JT, Prince C, Story JY, Branella GM, Lytle AM, Fedanov A, Alexander JS, Porter CC, Doering CB, Spencer HT, Chandrakasan S. Thrombopoietin-based CAR-T cells demonstrate in vitro and in vivo cytotoxicity to MPL positive acute myelogenous leukemia and hematopoietic stem cells. Gene Ther. 2022 05; 29(5):1-12.
-
Mesa R, Jamieson C, Bhatia R, Deininger MW, Gerds AT, Gojo I, Gotlib J, Gundabolu K, Hobbs G, Klisovic RB, Kropf P, Mohan SR, Oh S, Padron E, Podoltsev N, Pollyea DA, Rampal R, Rein LA, Scott B, Snyder DS, Stein BL, Verstovsek S, Wadleigh M, Wang ES, Bergman MA, Gregory KM, Sundar H. Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2016 12; 14(12):1572-1611.
-
Waisbren J, Dinner S, Altman J, Frankfurt O, Helenowski I, Gao J, McMahon BJ, Stein BL. Disease characteristics and prognosis of myelodysplastic syndrome presenting with isolated thrombocytopenia. Int J Hematol. 2017 Jan; 105(1):44-51.
-
Stein BL, Gotlib J, Arcasoy M, Nguyen MH, Shah N, Moliterno A, Jamieson C, Pollyea DA, Scott B, Wadleigh M, Levine R, Komrokji R, Klisovic R, Gundabolu K, Kropf P, Wetzler M, Oh ST, Ribeiro R, Paschal R, Mohan S, Podoltsev N, Prchal J, Talpaz M, Snyder D, Verstovsek S, Mesa RA. Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms. J Natl Compr Canc Netw. 2015 Apr; 13(4):424-34.
-
Cleyrat C, Darehshouri A, Steinkamp MP, Vilaine M, Boassa D, Ellisman MH, Hermouet S, Wilson BS. Mpl traffics to the cell surface through conventional and unconventional routes. Traffic. 2014 Sep; 15(9):961-82.
-
Patil AS, Dotters-Katz SK, Metjian AD, James AH, Swamy GK. Use of a thrombopoietin mimetic for chronic immune thrombocytopenic purpura in pregnancy. Obstet Gynecol. 2013 Aug; 122(2 Pt 2):483-485.
-
Metjian A, Abrams CS. New insights and therapeutics for immune-mediated thrombocytopenia. Expert Rev Cardiovasc Ther. 2008 Jan; 6(1):71-84.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|